Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
94.56
+6.88 (7.85%)
At close: Jun 29, 2026, 4:00 PM EDT
92.67
-1.89 (-2.00%)
After-hours: Jun 29, 2026, 7:42 PM EDT
Monopar Therapeutics Employees
Monopar Therapeutics had 22 employees as of December 31, 2025. The number of employees increased by 6 or 37.50% compared to the previous year.
Employees
22
Change (1Y)
6
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$681,135
Market Cap
633.44M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | 6 | 37.50% | 22 | 0 |
| Dec 31, 2024 | 16 | 6 | 60.00% | 14 | 2 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2022 | 12 | 2 | 20.00% | 11 | 1 |
| Dec 31, 2021 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| 4D Molecular Therapeutics | 196 |
| CorMedix | 191 |
| BridgeBio Oncology Therapeutics | 106 |
| Tectonic Therapeutic | 60 |
| Crescent Biopharma | 55 |
| Faeth Therapeutics | 29 |
MNPR News
- 3 days ago - Monopar Therapeutics announces new FoCus trial analyses - TheFly
- 3 days ago - Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - GlobeNewsWire
- 7 days ago - Monopar Therapeutics management to meet virtually with Piper Sandler - TheFly
- 25 days ago - Monopar Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Monopar Therapeutics presents ALXN1840-WD-205 data at EASL - TheFly
- 4 weeks ago - Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 - GlobeNewsWire
- 5 weeks ago - Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - GlobeNewsWire
- 6 weeks ago - Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire